En­ta­sis lands first an­tibi­ot­ic ap­proval eight years af­ter spin­ning out of As­traZeneca

Al­most eight years af­ter spin­ning out As­traZeneca’s an­tibi­otics pipeline, En­ta­sis Ther­a­peu­tics has land­ed its first ap­proval.

The FDA ap­proved its Xac­duro, made up of sul­bac­tam and dur­lobac­tam in­jec­tions, as a treat­ment for pneu­mo­nia caused by dif­fi­cult-to-treat bac­te­ria strains known as Acine­to­bac­ter bau­man­nii-cal­coaceti­cus com­plex (A. bau­man­nii) among adult pa­tients. Par­tic­u­lar­ly among al­ready vul­ner­a­ble hos­pi­tal­ized pa­tients, these in­fec­tions can be dead­ly.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN